Lupin signs agreement with TTP plc UK for soft-mist inhalation technology platform
#Lupin #TTP #TheTechnologyPartnership #InhalationDrugs #InhalationTechnology #InhalationProducts #SMITechnology #InhalationDevice #DrugDeliveryDeviceTo acquire the exclusive worldwide rights to develop, manufacture and commercialize inhalation products
December 2021 : Lupin Inc., a wholly-owned subsidiary of global pharma major, Lupin Limited (Lupin) has entered into an agreement with TTP plc (The Technology Partnership plc) to acquire the exclusive worldwide rights to develop, manufacture and commercialize inhalation products using TTP’s soft-mist inhalation technology platform. By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhaled medicines to patients across the globe.
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants. The individual doses are delivered using a precisely engineered nozzle system to produce a slow-moving and long-sustaining aerosol cloud. Lupin anticipates applications across respiratory care.
Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialize the products globally.
Commenting on the development Vinita Gupta, Global CEO, Lupin said, “Inhalation is a strategic pillar of Lupin’s growth story, as we strive to bring affordable medicines to patients across the globe. The partnership with TTP for SMI technology platform is a strategic addition to our broad inhalation capabilities.”
Alok Sonig, CEO - US Generics & Global R&D Head, Lupin added, “Lupin is excited to be partnering with TTP. The organizations will work together to develop products using TTP’s SMI technology that complement Lupin’s portfolio of complex inhalation products.”
Commenting on the development, Sam Hyde, Managing Director, TTP said, “We are excited to be partnering with Lupin to commercialize our SMI technology so that it can benefit patients suffering with chronic respiratory conditions. TTP has deep expertise in aerosol science, and we have been working with our clients for over 30 years in complex drug delivery device development – this partnership represents an exciting next step for us in this innovative area of respiratory drug delivery.”
NEWSLETTER
TRENDING ON PRO MFG
MORE FROM THE SECTION
